ENTITY
Hangzhou Tigermed Consulting (A)

Hangzhou Tigermed Consulting (A) (300347 CH)

142
Analysis
Health Care • China
Hangzhou Tigermed Consulting Company Limited provides professional clinical research services for domestic and foreign pharmaceutical and health-related research and development. The Company's main services include clinical trial technology services, data management, and statistical analysis.
more
•04 Sep 2021 22:37

Novotech Health IPO Initiation: On-Demand Science

Novotech is set to pre-market an HKEx IPO to raise up to $1.5 bn. Novotech’s fundamentals are solid and the IPO is worth a look for investors...

Logo
456 Views
Share
•27 Jul 2021 10:03

Asymchem Labs A/H Listing Early Look - Fast Growing, Relatively Insulated

Asymchem Laboratories (002821 CH) (AL) aims to raise around US$1-1.5bn in its H-share listing in Hong Kong. The A-shares listed were listed in...

Logo
453 Views
Share
bullish•Wuxi Biologics
•20 Jul 2021 18:54

Wuxi Biologics Placement - Similar Deal Will Yield Similar Results

Wuxi Biologics Holdings is looking to raise up to US$1.3bn by selling about 1.8% of Wuxi Biologics (2269 HK). This is the company's 15th placement...

Logo
597 Views
Share
•25 Feb 2021 17:41

JOINN Laboratories IPO: Trading Debut

The grey market price varies from HK$146.70-HK$142.00 per H-share vs listing price of HK$151. JOINN is fairly priced at the H-share listing price...

Logo
537 Views
Share
•17 Feb 2021 01:43

JOINN Laboratories IPO: Valuation Insights

JOINN has launched its HK IPO at an indicative price range of HK$133-151 per H-share. The combination of a reasonable AH discount and relative...

Logo
556 Views
Share
x